Eli Lilly and

LLY · NYSE · USD

$1,142.85−0.61%−$7.00

Close · October 2, 2026

At a glance

Revenue growth: +44.70%; 2025 vs 2024
Net income growth: +94.90%; 2025 vs 2024
Net margin: 31.7%; 2024: 23.5%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	22,974	19,799	19,292	17,601	15,558	12,729	13,533	11,439	11,303	8,768	9,353	9,499
Cost of revenue	3,268	3,577	3,372	3,008	2,448	2,225	2,404	2,171	2,170	1,674	1,788	1,860
Gross profit	19,706	16,222	15,920	14,593	13,110	10,504	11,130	9,268	9,133	7,095	7,565	7,639
Selling, general and administrative	3,430	2,934	3,458	2,627	2,753	2,468	2,771	1,984	2,003	1,836	1,810	1,688
Research and development	3,819	3,510	3,802	3,466	3,336	2,734	3,023	2,734	2,711	2,523	2,563	2,409
Operating income	12,457	9,778	8,661	8,500	7,021	5,302	5,336	4,550	4,419	2,736	3,193	3,541
EBIT	12,457	9,778	8,661	8,500	7,021	5,302	5,336	4,550	4,419	2,736	3,193	3,541
EBITDA	12,991	10,287	9,247	8,970	7,499	5,765	5,821	5,017	4,833	3,136	3,581	3,952
Interest expense	345	332	153	180	249	244	131	193	184	180	138	125
Pre-tax income	9,247	8,850	8,266	7,232	6,777	3,456	5,038	1,588	3,517	2,536	2,509	427
Income tax	2,152	1,454	1,629	1,650	1,116	697	629	618	550	293	319	485
Net income	7,095	7,396	6,638	5,583	5,661	2,759	4,410	970	2,967	2,243	2,190	-57.4
Net income to common shareholders	7,095	7,396	6,638	5,583	5,661	2,759	4,410	970	2,967	2,243	2,190	-57.4
Basic EPS	7.95	8.27	7.39	6.22	6.30	3.07	4.88	1.08	3.29	2.49	2.42	-0.06
Diluted EPS	7.94	8.26	7.39	6.21	6.29	3.06	4.88	1.07	3.28	2.48	2.42	-0.06
Average shares (basic)	892	895	898	897	898	899	903	901	901	901	904	900
Average shares (diluted)	894	896	898	899	900	901	903	905	904	904	904	900
Dividend per share	1.73	1.73	1.50	1.50	1.50	1.50	1.30	1.30	1.30	1.30	1.13	1.13